<DOC>
	<DOC>NCT01471860</DOC>
	<brief_summary>The purpose of this clinical investigation is to evaluate the efficacy and safety of the CVRx Barostim Neo System in the treatment of patients with heart failure.</brief_summary>
	<brief_title>Barostim Neo System in the Treatment of Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age at least 21 years Symptomatic heart failure despite optimal, stable pharmacological therapy for at least 4 weeks Significant carotid plaque or stenosis Known or suspected baroreflex failure or autonomic neuropathy Myocardial infarction, unstable angina, syncope, cerebral vascular accident, SCD, or received defibrillation therapy within the past 3 months Heart failure secondary to a reversible condition</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>